What is the PIVKAII value in early-stage liver cancer?

PIVKA-II value generally refers to the PIVKA-Ⅱ level, which is an important serological blood marker for diagnosing liver cancer and can be detected in the serum of patients during the early stages of the disease. Typically, the average PIVKA-Ⅱ level in early-stage liver cancer patients is approximately 900 ng/mL. A detailed analysis is as follows:

PIVKA-II is one of the key serological markers for liver cancer diagnosis. Clinically, a threshold of 40 ng is commonly used as the diagnostic cutoff. In most patients with early-stage liver cancer, PIVKA-II levels are significantly elevated, with average values reaching around 900 ng/mL. Therefore, if abnormal levels of this marker are detected, early liver cancer should be suspected. However, a definitive diagnosis of liver cancer cannot be made based solely on PIVKA-Ⅱ levels; it must be combined with other imaging studies, pathological examinations, and comprehensive clinical evaluations. If other potential influencing factors have been ruled out and the PIVKA-Ⅱ level progressively increases beyond 1000 ng/mL, this warrants serious attention and further investigation to avoid delays in diagnosis and treatment.

Patients are advised to seek medical attention promptly if they experience any symptoms or discomfort. Early detection and timely treatment of liver cancer can significantly improve survival rates and chances of cure.